AcouSort AB

AcouSort AB

SSTO:ACOU
2.57
SEK
-0.04
(-1.53%)
-0.51EPS
79.79MMarket Cap
Nov 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.07
0.24
0.2
0.34
0.32
0.1
0.18
0.43
0.23
0.38
0.42
0.32
0.36
0.37
Basic EPS, GAAP
-0.01
0.01
-0.03
-0.1
-0.78
-0.87
-0.93
-0.7
-0.93
-1.04
-1.29
-1.01
-0.64
-0.52
Free Cash Flow per Basic Share
- -
- -
-0.09
-0.03
-1.1
-0.71
-0.95
-0.62
-0.83
0.3
-2.37
-1.26
-0.89
-0.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.03
0.04
0.01
1.24
0.48
1.56
0.59
0.82
2.49
1.43
1.62
0.57
0.77
0.46
Tangible Book Value per Share
0.03
0.04
0.01
1.24
0.44
1.5
0.49
0.7
2.33
1.22
1.38
0.27
0.54
0.23
Basic Weighted Avg Shares
11
8
8
8
8
10
10
11
13
13
13
15
19
22
Sales/Revenue/Turnover
1
2
2
3
2
1
2
5
3
5
6
5
7
8
Operating Margin (%)
-22.32
6.98
-18.73
-23.62
-244.64
-835.29
-519.72
-158.56
-406.65
-289.12
-315.97
-340.41
-159.39
-147.6
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
-6
-9
-10
-8
-12
-14
-17
-15
-12
-11
Effective Tax Rate (%)
- -
9.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7.53
5.55
-17.71
-30.49
-244.64
-834.26
-520.31
-161.89
-408.18
-277.65
-308.8
-318.3
-177.34
-140.82
Working Capital
- -
- -
- -
-1
3
15
5
7
30
16
20
4
11
5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
10
4
16
6
10
33
19
24
8
16
10
Return on Invested Capital (%)
- -
9.09
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
8.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
35.59
-127.84
-16.54
-87.76
-92.08
-89.83
-102.85
-57.61
-53.03
-79.33
-92.51
-98.15
-72.26

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
60
60
80

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
13
22
16
Cash, Cash Equivalents & STI
6
15
9
Accounts Receivable, Net
- -
- -
1
Inventories
3
3
2
Total Current Liabilities
2
13
12
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,299.82%
51.34%
92.61%
Free Cash Flow
277.63%
-205.39%
-10.78%
Net Income, GAAP
92.6%
11.79%
-19.4%
Sales/Revenue/Turnover
31.35%
13.57%
44.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
5
2025
2
2
1
2
7
2026
2
2
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.25
-0.32
-0.25
-0.19
-1.01
2025
-0.27
-0.14
-0.12
-0.12
-0.64
2026
-0.11
-0.17
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Torsten Freltoft
Full Time Employees
11
Sector
Distribution services
Industry
Medical distributors
Address
Building 406 Lund SN Sweden 223 81
IPO Date
Jan 9, 2017
Business
AcouSort AB (publ) (ACOU.ST) develops acoustofluidic components and instruments for automated sample preparation in diagnostics, analytics, cell therapy processing, flow cytometry, and quality control applications; core products include separation modules for continuous cell washing, up-concentration, and isolation; trapping modules for capturing particles and cells in microfluidic systems; AQC modules for in-line optical analysis of suspensions; AcouPlasma modules enabling blood plasma separation from whole blood without centrifugation; benchtop research instruments such as AcouTrap for handling cells, extracellular vesicles, bacteria, and viruses in 96-well format, and AcouWash for label-free target cell separation from diverse samples; as well as evaluation kits for technology integration testing. Founded in 2010 and headquartered in Medicon Village, Lund, Sweden, the company targets life science instrument manufacturers, researchers, and clinicians primarily in Europe, North America, and Asia. Recent developments include Werfen's 2024 launch of the GEM Premier 7000 point-of-care blood gas analyzer incorporating AcouSort's hemolysis detection technology, generating minimum royalty income of SEK 5.25 million in 2025; a May 2025 rights issue raising SEK 24.9 million to fund OEM partnerships through 2027; extensions and new orders in 2025 from Central European diagnostic firms, a leading pharma for AcouWash quality control (EUR 11,300 extension in April), a US cell therapy partner, and UK sepsis management collaborator; March 2025 letter of intent with Bio-ReCell for stem and immune cell isolation from adipose tissue; November 2025 technology evaluation agreement with SeeQ Diagnostics for blood sample preparation; and ongoing collaborations with flow cytometer makers, GenSensor for bioreactor monitoring, and academic institutions like University of Ottawa.